Brief: Imaging Biometrics Directors Decide Against Phase 2 Trial Of Gallium Maltolate
16/01/2026 07:13
Jan 16 (Reuters) - Imaging Biometrics Ltd IBAI.L: IMAGING BIOMETRICS LTD - DIRECTORS DECIDE AGAINST PHASE 2 TRIAL OF GALLIUM MALTOLATE Source text: ID:nRSP1365Pa Further company coverage: IBAI.L ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Imaging Biometrics
See all newsImaging Biometrics - US Academic Medical Centre Adopts IB Clinic
Imaging Biometrics - Half Yearly Report to 30 June 2026
Imaging Biometrics - Sub-division
Brief: Imaging Biometrics Says Oral Gallium Maltolate Safe And Well Tolerated Up To 2500 Mg/Day
Brief: Imaging Biometrics Says Expectation Of Progress Towards Profitability In 2026 Is Unchanged